Trump Adds Nine Drugmakers to Medicaid Price Deal, Now Covering 89% of the Market

President Trump announced Monday that nine more pharmaceutical manufacturers — including Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB — have agreed to “most-favored-nation” pricing deals tying their U.S. Medicaid prices to the lower prices those companies charge in other wealthy nations. The announcement, made at the White House alongside HHS Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick and Dr. Mehmet Oz, brings the total number of manufacturers with MFN agreements to 26, covering roughly 89% of the branded drug market [1, 2]. The deals apply to drugs treating hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease and various cancers, and extend most-favored-nation pricing to every state Medicaid program in the country [2].

Why It Sucks:

Trump Administration and Conservatives

• Historic drug savings without price controls. Supporters argue the deal achieves lower drug prices through voluntary negotiation with industry rather than the government-mandated price caps Democrats have pushed, calling it proof that market-based dealmaking works [1, 2].
• Nearly the entire branded market now covered. With 26 manufacturers representing 89% of the branded drug market signed on, backers say the administration has delivered a scale of reform that previous administrations only talked about [2].
• Direct relief for the most vulnerable patients. Because the deals apply to state Medicaid programs, conservatives frame this as targeted help for lower-income patients dealing with costly chronic and rare diseases [2].

Progressive Drug-Pricing Advocates

• Voluntary deals lack enforcement teeth. Critics note these are negotiated agreements, not binding law, and argue a future administration or the companies themselves could walk away with no legal consequence, unlike the drug-pricing provisions Democrats passed into statute under the Inflation Reduction Act [1].
• Commercial insurance prices untouched. The deals apply to state Medicaid pricing, leaving the higher prices most working Americans pay through employer or marketplace insurance largely unaddressed [2].
• Timed for midterm optics. Coming just over two months before the midterm elections, skeptics argue the rolling announcements of “nine more companies” are being staged for maximum political benefit rather than delivering pricing certainty all at once [1].

Pharmaceutical Industry

• Revenue hit threatens R&D investment. Industry representatives warn that tying U.S. Medicaid prices to lower international prices squeezes the margins that fund the next generation of drug development, particularly for treatments of rare diseases like hemophilia named in this deal [2].
• Pressure to sign under political weight. With 26 companies now in and the administration publicly naming holdouts round after round, manufacturers argue they face mounting political pressure to accept terms rather than negotiate freely [1, 2].
• Uncertainty for smaller manufacturers. This round specifically targets mid-sized companies, which industry groups say have less room to absorb reduced margins than larger firms already locked into earlier deals [2].

Sources & Citations:

[1] Yahoo Finance: Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms
[2] The White House: Fact Sheet — Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers